Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): modelling to estimate long-term survival, quality-adjusted survival and cost benefit

Beth S Woods, Eleftherios Sideris, Matthew R Sydes, Mellisa Gannon, Mahesh KB Parmar, Mymoona Alzouebi, Gerhardt Attard, Alison J. Birtle, Susannah Brock, Richard Cathomas, Prabir R. Chakraborti, Audrey Cook, William R Cross, David P Dearnaley, Stephanie Gibbs, John D. Graham, Joanna Gale, Robert hughes, Rob Jones, Robert LaingMalcolm D Mason, Duncan McLaren, David Matheson, Robin Millman, Joe O’Sullivan, Omi Parikh, Chris Parker, Clive Peedell, Andrew Protheroe, Alastair WS Ritchie, Angus J. Robinson, Martin Russell, Matthew S Simms, Narayanan N Srihari, Rajaguru Srinivasan, John Staffurth, Santhanam Sundar, George N Thalmann, Shaun Tolan, Anna TH Tran, David Tsang, John Wagstaff, Nicholas D. James, Mark J. Sculpher

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)449-458
Number of pages9
JournalEuropean Urology Oncology
Volume1
Issue number6
Early online date14 Sep 2018
DOIs
Publication statusPublished - 1 Dec 2018

Cite this